Sun Pharmaceutical's wholly owned subsidiaries has launched in US, the authorized generic (AG) version for Daiichi Sankyo Inc.’s Welchol (colesevelam hydrochloride) 625mg tablets.
The launch is pursuant to a distribution and supply agreement between Sun Pharma’s wholly owned subsidiary and Daiichi Sankyo Inc., which grants the Sun Pharma subsidiary, exclusive rights to distribute these tablets in the US for a pre-determined period.
Welchol tablets recorded US sales of approximately US$ 520 million for the 12 months ending March 2018, as per IQVIA.